HDL-C and the diabetic patient: Target for therapeutic intervention?

Diabetes Research and Clinical Practice

Volumn 68, Issue SUPPL. 2, 2005, Pages

  Rosenson, Robert S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

HDL C; Lipid lowering; Metabolic syndrome; Rosuvastatin; Statin

Indexed keywords

ATORVASTATIN; CREATINE KINASE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; METABOLIC SYNDROME X;

EID: 20444423628     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.013     Document Type: Conference Paper

References (46)

1. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 1998 229 234
2. H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, and J. Tuomilehto The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
4. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, and J. Dallongeville European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice Eur. Heart J. 24 2003 1601 1610
5. H.B. Brewer Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 24 2004 387 391
6. M.I. Mackness, S. Arrol, C. Abbott, and P.N. Durrington Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
7. M. Navab, S.Y. Hama, G.M. Anantharamaiah, K. Hassan, G.P. Hough, and A.D. Watson Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low-density lipoprotein: steps 2 and 3 J. Lipid Res. 41 2000 1495 1508
8. M. Navab, S.Y. Hama, C.J. Cooke, G.M. Anantharamaiah, M. Chaddha, and L. Jin Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1 J. Lipid Res. 41 2000 1481 1494
9. A. Uittenbogaard, P.W. Shaul, I.S. Yuhanna, A. Blair, and E.J. Smart High-density lipoprotein prevents oxidized low-density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae J. Biol. Chem. 275 2000 11278 11283
10. L. Rohrer, M. Hersberger, and A. von Eckardstein High-density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease Curr. Opin. Lipidol. 15 2004 269 278
11. R.S. Rosenson, J.D. Otvos, and D.S. Freedman Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am. J. Cardiol. 90 2002 89 94
12. S.M. Haffner, L. Mykkänen, D. Robbins, R. Valdez, H. Miettinen, and B.V. Howard A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects Diabetologia 38 1995 1328 1336
13. S.M. Grundy Hypertriglyceridemia, insulin resistance, and the metabolic syndrome Am. J. Cardiol. 83 1999 25F 29F
14. B. Lamarche, I. Lemieux, and J.P. Després The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects Diabetes Metab. 25 1999 199 211
15. H.N. Ginsberg, and L.S. Huang The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis J. Cardiovasc. Risk 7 2000 325 331
16. J. de Graaf, H.L. Hak-Lemmers, M.P. Hectors, P.N. Demacker, J.C. Hendriks, and A.F. Stalenhoef Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects Arterioscler. Thromb. 11 1991 298 306
17. S. Dejager, E. Bruckert, and M.J. Chapman Dense low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia J. Lipid Res. 34 1993 295 308
18. V. Anber, B.A. Griffin, M. McConnell, C.J. Packard, and J. Shepherd Influence of plasma lipid and LDL-subfraction profile on the interaction between low-density lipoprotein with human arterial wall proteoglycans Atherosclerosis 124 1996 261 271
19. B.A. Griffin Lipoprotein atherogenicity: an overview of current mechanisms Proc. Nutr. Soc. 58 1999 163 169
20. H. Ohmura, H. Mokuno, M. Sawano, C. Hatsumi, Y. Mitsugi, and Y. Watanabe Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B Metabolism 51 2002 1081 1087
21. R.S. Rosenson Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities Atherosclerosis 173 2004 1 12
22. S.A. Thorne, S.E. Abbot, P.G. Winyard, D.R. Blake, and P.G. Mills Extent of oxidative modification of low-density lipoprotein determines the degree of cytotoxicity to human coronary artery cells Heart 75 1996 11 16
23. J.L. Mehta, D.Y. Li, H.J. Chen, J. Joseph, and F. Romeo Inhibition of LOX-1 by statins may relate to upregulation of eNOS Biochem. Biophys. Res. Commun. 289 2001 857 861
24. W.T. Garvey, S. Kwon, D. Zheng, S. Shaughnessy, P. Wallace, and A. Hutto Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 52 2003 453 462
25. J. Otvos, W. Cromwell, I. Shalaurova, and E. Schaefer LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study Circulation 108 Suppl. 4 2003 740 741
26. R.S. Rosenson, New approaches in the intensive management of cardiovascular risk in the metabolic syndrome, Curr. Probl. Cardiol. (2005), in press.
27. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am. J. Cardiol. 90 2002 22i 29i
28. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
29. D.R. Jacobs Jr., I.L. Mebane, S.I. Bangdiwala, M.H. Criqui, and H.A. Tyroler High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study Am. J. Epidemiol. 131 1990 32 47
30. G. Assmann, and H. Schulte Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study Am. J. Cardiol. 70 1992 733 737
31. D.J. Gordon HDL and CHD-an epidemiological perspective J. Drug Dev. 3 1990 11 17
32. J.D. Otvos, D. Collins, D.S. Freedman, C. Pegus, E.J. Schaefer, and S.J. Robins LDL and HDL particle subclasses are independent predictors of cardiovascular events in the Veteran Affairs HDL Intervention Trial Circulation 106 Suppl. 2 2002 729 730
33. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
34. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
35. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 2004 S68 S71
36. C.M. Ballantyne, J.A. Herd, L.L. Ferlic, J.K. Dunn, J.A. Farmer, and P.H. Jones Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 1999 736 743
37. D.W. Schneck, R.H. Knopp, C.M. Ballantyne, R. McPherson, R.R. Chitra, and S.G. Simonson Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease Am. J. Cardiol. 91 2003 33 41
38. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, and E. Miller Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial) Am. J. Cardiol. 92 2003 152 160
39. P.C. Deedwania, D.B. Hunninghake, H.E. Bays, P.H. Jones, V.A. Cain, and J.W. Blasetto For the STELLAR Study Group, effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome Am. J. Cardiol. 95 2005 360 366
40. J.R. Schaefer, H. Schweer, K. Ikewaki, H. Stracke, H.J. Seyberth, and H. Kaffarnik Metabolic basis of high-density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease Atherosclerosis 144 1999 177 184
41. C. Berne, and A. Siewert-Delle Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: results of the URANUS study Atherosclerosis Suppl. 5 2004 107
42. D.J. Betteridge, and M. Gibson Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study Atherosclerosis Suppl. 5 2004 107
43. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, and M.B. Elam Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein cholesterol Intervention Trial Study Group N. Engl. J. Med. 341 1999 410 418
44. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, and J.S. Morse Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N. Engl. J. Med. 345 2001 1583 1592
45. X.Q. Zhao, J.S. Morse, A.A. Dowdy, N. Heise, D. DeAngelis, and J. Frohlich Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) Am. J. Cardiol. 93 2004 307 312
46. P.N. Durrington, J. Tuomilehto, A. Hamann, D. Kallend, and K. Smith Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia Diabetes Res. Clin. Pract. 64 2004 137 151